Key result
Prorenin receptor monoclonal antibody cuts glioblastoma tumor volume ~37% in a xenograft model.
Why the study?
The (pro)renin receptor was previously identified as a potential target for glioma therapy by gene silencing, prompting evaluation of a monoclonal antibody against it.
Does a monoclonal antibody against (P)RR reduce gliomagenesis in glioma cell lines and xenograft models?
Does a monoclonal antibody against (P)RR reduce gliomagenesis in glioma cell lines and xenograft models?
Answers are grounded in this paper and cite their sources.
A monoclonal antibody against the (pro)renin receptor suppresses gliomagenesis in vitro and in vivo, suggesting a potential therapeutic strategy for glioblastoma.
Glioblastoma is characterized by a strong self-renewal potential and poor differentiated state. We have reported previously that the (pro)renin receptor [(P)RR] is a potential target for glioma therapy by silencing the (P)RR gene. Here, we have examined the effects of a monoclonal antibody against (P)RR on gliomagenesis. Methods: Human glioma cell lines (U251MG and U87MG) and a glioma stem cell line (MGG23) were used for the in vitro study. The expressions of the Wnt/β-catenin signaling pathway (Wnt signaling pathway) components and stemness markers were measured by Western blotting. The effects of the (P)RR antibody on cell proliferation, sphere formation, apoptosis and invasion were also examined. Subcutaneous xenografts were also examined in nude mice. Results: Treatment with the (P)RR antibody reduced expression of Wnt signaling pathway components and stemness markers. Furthermore, the (P)RR antibody reduced cell proliferation and decreased sphere formation significantly. The treatment also suppressed invasion and induced apoptosis. In a subcutaneous xenograft model, systemic administration of the (P)RR antibody reduced tumor volume significantly. Conclusion: These data show that treatment with the (P)RR antibody is a potential therapeutic strategy for treating glioblastoma.
No takes yet. Share an insight, caveat, or question.
Fujimori et al. (2022) studied Glioblastoma (n=56). Monoclonal antibody against (pro)renin receptor vs. Control supernatant medium was evaluated on Tumor volume in subcutaneous xenograft model at 20 days (mL) (p=<0.01). Systemic administration of a monoclonal antibody against the (pro)renin receptor reduced tumor volume in a glioblastoma xenograft model.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: